摘要
目的观察阿托伐他汀干预后脑梗死患者高敏C反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)水平变化。方法选取急性动脉粥样硬化性血栓性脑梗死44例,分为两组,分别服用阿托伐他汀、阿司匹林组(A组)和单独服用阿司匹林组(NA组),测定3个月前后hs-CRP、MMP-9和血脂水平的变化。结果 A组hs-CRP,MMP-9水平均较治疗前显著下降(P<0.05),而NA组治疗前后无明显变化。治疗前后血脂水平比较A组TC、LDL-C水平显著下降,NA组变化不明显,TG在两组变化均不明显。结论阿托伐他汀可能通过减轻炎症反应来稳定颈动脉粥样硬化斑块,从而降低脑血管疾病的发生率和病死率。
Objective To detection hs-CRP and MMP-9 levels of atorvastatin intervention patients after infarction and investigate the mechanisms of atorvastatin in cerebral infarction preventing. Methods Totally 44 cases of acute atherosclerotic thrombotic cerebral infarction patients were randomly divided into two groups, taking atorvastatin and aspirin group （A）, aspirin alone group （NA）. The levels of hs-CRP, MMP - 9 and blood lipid in serum Were measured before and three months after therapy. Results After treatment, levels of hs-CRP and MMP-9 in group A were decrease significantly, but there were no significant difference in group NA. Compared with group NA, levels of TC and LDL-C in group A were decrease significantly. TG was not changed significantly in both groups. Conclusions Atorvastatin may reduce the inflammation reaction and the stabilization of carotid artery atherosclerosis plaque, and reduce the incidence of cerebral infarction and mortali ty.
出处
《卒中与神经疾病》
2014年第1期23-25,F0004,共4页
Stroke and Nervous Diseases
基金
山西省高校科技研究开发项目(编号20091181)
关键词
阿托伐他汀
炎症
颈动脉粥样硬化
脑梗死
MMP-9
Atorvastatin Inflammation Carotid atherosclerosis Cerebral infarction hs-CRP MMP-9
